Harrow (HROW) closed at $29.37 on November 11, 2026, down 3.3% from the previous close, on volume of 938,182 shares (30-day average 650,843).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Call Spread | 17-Dec-2740 : 50 C | 1,960 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Harrow’s Strong VEVYE and IHEEZO Momentum Supports Buy Rating; $70 Price Target Unchanged
TipRanks (Wed, 11-Nov 7:36 AM ET)
TipRanks (Wed, 11-Nov 5:26 AM ET)
Harrow stock jumps as eye-care products deliver record Q3 sales
Seeking Alpha News (Tue, 10-Nov 11:22 AM ET)
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), Harrow Health (HROW)
TipRanks (Tue, 10-Nov 10:40 AM ET)
Harrow Health Reports Record Third-Quarter Revenue and Earnings
TipRanks (Mon, 9-Nov 5:11 PM ET)
Harrow Health GAAP EPS of $0.25 beats by $0.06, revenue of $99.3M beats by $0.71M
Seeking Alpha News (Mon, 9-Nov 4:23 PM ET)
Harrow Announces Third Quarter 2026 Financial Results
Globe Newswire (Mon, 9-Nov 4:02 PM ET)
Business Wire (Mon, 2-Nov 9:00 AM ET)
Harrow Launches HarrowRx Platform
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
Globe Newswire (Mon, 26-Oct 7:00 AM ET)
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Harrow trades on the NASDAQ stock market under the symbol HROW.
As of November 11, 2026, HROW stock price declined to $29.37 with 938,182 million shares trading.
HROW has a beta of 2.10, meaning it tends to be more sensitive to market movements. HROW has a correlation of 0.14 to the broad based SPY ETF.
HROW has a market cap of $1.10 billion. This is considered a Small Cap stock.
Last quarter Harrow reported $99 million in Revenue and $.25 earnings per share. This beat revenue expectation by $734,688 and missed earnings estimates by -$.06.
In the last 3 years, HROW traded as high as $59.23 and as low as $7.60.
The top ETF exchange traded funds that HROW belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWO.
HROW has underperformed the market in the last year with a return of -14.0%, while the SPY ETF gained +12.6%. In the last 3 month period, HROW fell short of the market, returning -27.8%, while SPY returned -1.5%. However, in the most recent 2 weeks HROW has outperformed the stock market by returning +1.0%, while SPY returned -1.3%.
HROW support price is $29.16 and resistance is $31.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HROW shares will trade within this expected range on the day.
